Current and future treatment modalities for Clostridium difficile-associated disease

American Journal of Health-System Pharmacy

Volumn 65, Issue 8, 2008, Pages 705-715

  Halsey, Jennifer ^a  

^a West Allis Hospital   (United States)

Author keywords

Antibiotics; Antiinfective agents; Antiprotozoals; Bile acid resins; Clostridium difficile; Clostridium infections; Diagnosis; Enterocolitis; Globulin immune; Metronidazole; Nitazoxanide; Probiotics; Resistance; Rifaximin; Serums; Toxicity; Vaccines; Vancomycin

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL VACCINE; BILE ACID SEQUESTRANT; CEFAZOLIN; CEFTAZIDIME; CEPHALOSPORIN; CIPROFLOXACIN; CLOSTRIDIUM TOXIN; CLOSTRIDIUM TOXIN A; CLOSTRIDIUM TOXIN B; COLESTIPOL; COLESTYRAMINE; FLAGELLAR CAP PROTEIN; FLAGELLIN; FUSIDIC ACID; HISTAMINE H2 RECEPTOR ANTAGONIST; IMIPENEM; IMMUNOGLOBULIN; METRONIDAZOLE; NISIN; NITAZOXANIDE; PLACEBO; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAXIMIN; TEICOPLANIN; TOLEVAMER; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DISINFECTION; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG TREATMENT FAILURE; FLUID RESUSCITATION; GASTROINTESTINAL DISEASE; HOSPITAL INFECTION; HUMAN; HYPERCHOLESTEROLEMIA; INFECTION PREVENTION; INFECTION RISK; INFECTIOUS DIARRHEA; LACTOBACILLUS PARACASEI; LACTOBACILLUS PLANTARUM; NONHUMAN; PATHOGENICITY; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; SACCHAROMYCES BOULARDII; SINGLE DRUG DOSE; TREATMENT DURATION;

EID: 42349087941     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070077     Document Type: Review

References (106)

1. Al-Tureihi FJ, Hassoun A, Wolf-Klein G et al. Albumin, length of stay, and proton pump inhibitors: key factors in Clostridium difficile-associated disease in nursing home patients. J Am Med Dir Assoc. 2005; 6:105-8.
2. Walker KJ, Gilliland SS, Vance-Bryan K et al. Clostridium difficile colonization in residents of long-term care facilities: prevalence and risk factors. J Am Geriatr Soc. 1993; 41:940-6.
3. Dial S, Alrasadi K, Manoukian C et al. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ. 2004; 171:33-8.
4. Pepin J, Saheb N, Coulombe MA et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile associated diarrhea. Clin Infect Dis. 2005; 41:1254-60.
5. Loo VG, Poirier L, Miller MA et al. A predominantly clonal multiinstitutional outbreak of Clostridium difficile- associated diarrhea with high morbidity and mortality. N Engl J Med. 2005; 353:2442-9.
6. Wistrom J, Norrby SR, Myhre EB et al. Frequency of antibiotic-associated diarrhoea in 2462 antibiotic-treated hospitalized patients: a prospective study. J Antimicrob Chemother. 2001; 47:43-50.
7. Dallal RM, Harbrecht BG, Boujoukas AJ et al. Fulminant Clostridium difficile: an underappreciated and increasing cause of death and complications. Ann Surg. 2002; 235:363-72.
8. Gerding DN. Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile-associated diarrhea: this is an antimicrobial resistance problem. Clin Infect Dis. 2004; 38:646-8.
9. McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis. 2006; 12:409-15.
10. Pepin J, Valiquette L, Alary ME et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ. 2004; 171:466-72.
11. Dial S, Delaney JA, Barkun AN et al. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA. 2005; 294:2989-95.
12. Cunningham R, Dale B, Undy B et al. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect. 2003; 54:243-5.
13. Thorens J, Froehlich F, Schwizer W et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine. Gut. 1996;39:54-9.
14. Rupnik M, Brazier JS, Duertden BI et al. Comparison of toxinotyping and PCR ribotyping of Clostridium difficile strains and description of novel toxinotypes. Microbiology. 2001; 147:439-47.
15. Rupnik M, Kato N, Grabnar M et al. New types of toxin A-negative, toxin B-positive strains among Clostridium difficile isolates from Asia. J Clin Microbiol. 2003; 41:1118-25.
16. Geric C, Rupnik M, Gerding DN et al. Distribution of Clostridium difficile variant toxinotypes and strains with binary toxin gene among clinical isolates in an American hospital. J Med Microbiol. 2004; 53:887-94.
17. Geric B, Johnson S, Gerding DN et al. Frequency of binary toxin genes among Clostridium difficile strains that do not produce large clostridial toxins. J Clin Microbiol. 2003; 41:5227-32.
18. McDonald LC, Killgore GE, Thompson A et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005; 353:2433-41.
19. Musher DM, Logan N, Mehendiratta V. Epidemic Clostridium difficile. N Engl J Med. 2006; 354:1199-200. Letter.
20. Akerlund T, Svenungsson B, Lagergren A et al. Correlation of disease severity with fecal toxin levels in patients with Clostridium difficile-associated diarrhea and distribution of PCR ribotypes and toxin yields in vitro of corresponding isolates. J Clin Microbiol. 2006; 44:353-8.
21. McCannell DR, Louie TJ, Gregson DB et al. Molecular analysis of Clostridium difficile PCR ribotype 027 isolates from Eastern and Western Canada. J Clin Microbiol. 2006; 44:2147-52.
22. Warny M, Pepin J, Fang A et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005; 366:1079-84.
23. Ticehurst JR, Aird DZ, Dam LM et al. Effective detection of toxigenic Clostridium difficile by a two-step algorithm including test for antigen and cytotoxin. J Clin Microbiol. 2006; 44:1145-9.
24. Mylonakis E, Ryan ET, Calderwood SB. Clostridium difficile-associated diarrhea: a review. Arch Intern Med. 2000; 161:525-33.
25. Laughon BE, Viscidi RP, Gdovin SL et al. Enzyme immunoassays for detection of Clostridium difficile toxins A and B in fecal specimens. J Infect Dis. 1984; 149:781-8.
26. Freeman J, Wilcox MH. The effects of storage conditions on viability of Clostridium difficile vegetative cells and spores and toxin activity in human faeces. J Clin Pathol. 2003; 56:126-8.
27. Delmee M, Van Broeck J, Simon A et al. Laboratory diagnosis of Clostridium difficile-associated diarrhea: a plea for culture. J Med Microbiol. 2005; 54:187-91.
28. Alfa MJ, Swan B, VanDekerkhove B et al. The diagnosis of Clostridium difficile- associated diarrhea: comparison of the Triage C. difficile panel, EIA for Tox A/B and cytotoxin assays. Diagn Microbiol Infect Dis. 2002; 43:257-63.
29. Staneck JL, Weckbach LS, Allen SD et al. Multicenter evaluation of four methods for Clostridium difficile detection: immunoCard C. difficile, cytotoxin assay, culture and latex agglutination. J Clin Microbiol. 1996; 34:2718-21.
30. Van den Berg RJ, Bruijnesteijn van Coppenraet LS, Gerritsen HJ et al. Prospective multicenter evaluation of a new immunoassay and real-time PCR for rapid diagnosis of Clostridium difficile-associated diarrhea in hospitalized patients. J Clin Microbiol. 2005; 43:5338-40.
31. Boyce JM, Pittet D. Guideline for hand hygiene in health-care settings: recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Infect Control Hosp Epidemiol. 2002; 23(12, suppl):S3-40.
32. Gordin FM, Schultz ME, Huber RA et al. Reduction in nosocomial transmission of drug-resistant bacteria after introduction of an alcohol-based handrub. Infect Control Hosp Epidemiol. 2005; 26:650-3.
33. Jernigan JA, Siegman-Tgra Y, Guerrant RC et al. A randomized crossover study of disposable thermometers for prevention of Clostridium difficile and other nosocomial infections. Infect Control Hosp Epidemiol. 1998; 19:494-9.
34. Lipsett PA, Samantaray DK, Tam ML et al. Pseudomembranous colitis: a surgical disease? Surgery. 1994; 116:491-6.
35. Gerding DN, Johnson S, Peterson LR et al. Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol. 1995; 16:459-77.
36. Fekety R. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. Am J Gastroenterol. 1997; 92:739-50.
37. American Society of Health-System Pharmacists. ASHP therapeutic position statement on the preferential use of metronidazole for the treatment of Clostridium difficile-associated disease. Am J Health-Syst Pharm. 1998; 55:1407-11.
38. Guerrant RL, Van Gilder T, Steiner TS et al. Practice guidelines for the management of infectious diarrhea. Clin Inf Dis. 2001; 32:331-51.
39. Flagyl (metronidazole) package insert. Chicago: Pharmacia; 2004.
40. Vancocin (vancomycin hydrochloride) package insert. Exton, PA: ViroPharma; 2005.
41. Thompson CM, Long SS, Gilligan PM et al. Absorption of oral vancomycin: possible associated toxicity. Int J Pediatr Nephrol. 1983; 4:1-4.
42. Spitzer PG, Eliopoulos GM. Systemic absorption of enteral vancomycin in a patient with pseudomembranous colitis. Ann Intern Med. 1984; 100:533-4.
43. Teasley DG, Gerding DN, Olson MM et al. Prospective randomized trial of metronidazole versus vancomycin for Clostridium difficile-associated diarrhea and colitis. Lancet. 1983; 2:1043-6.
44. Wilcox MH, Howe R. Diarrhoea caused by Clostridium difficile: response time for treatment with metronidazole and vancomycin. J Antimicrob Chemother. 1995; 36:673-9.
45. Fekety R, Silva J, Kauffman C et al. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med. 1989; 86:15-9.
46. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med. 1994; 330:257.
47. McFarland LV, Surawicz CM, Greenberg RN et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA. 1994; 271:1913-8.
48. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol. 2002; 97:1770-5.
49. Kucers A, Bennett NM, eds. The use of antibiotics. 4th ed. Philadelphia: Lippincott; 1987.
50. Wullt M, Odenholt I. A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhea. J Antimicrob Chemother. 2004; 54:211-6.
51. Noren T, Wullt M, Akerlund T et al. Frequent emergence of resistance in Clostridium difficile during treatment of C. difficile-associated diarrhea with fusidic acid. Antimicrob Agents Chemother. 2006; 50:3028-32.
52. De Lalla F, Nicolin R, Rinaldi E et al. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother. 1992; 36:2192-6.
53. Wenisch C, Parschalk B, Hasenhundl M et al. Comparison of vancomycin, teicoplanin, metronidazole and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis. 1996; 22:813-8. [Erratum, Clin Infect Dis. 1996; 23:423.]
54. Dworczynski A, Sokol B, Meisel-Mikolajczyk F. Antibiotic resistance of Clostridium difficile isolates. Cytobios. 1991; 65:149-53.
55. Taylor NS, Bartlett JG. Binding of Clostridium difficile cytotoxin and vancomycin by anion-exchange resins. J Infect Dis. 1980; 141:92-7.
56. Kruetzer EW, Milligan FD. Treatment of antibiotic-associated pseudomembranous colitis with cholestyramine resin. Johns Hopkins Med J. 1978; 143:67-72.
57. Tedesco FJ. Treatment of recurrent antibiotic-associated pseudomembranous colitis. Am J Gastroenterol. 1982; 77:220-1.
58. Mogg GA, Arabi Y, Youngs D et al. Therapeutic trials of antibiotic associated colitis. Scand J Infect Dis Suppl. 1980; 22:41-5.
59. Scott VN, Taylor SL. Effect of nisin on the outgrowth of Clostridium botulinum spores. J Food Sci. 1981; 46:117-20.
60. Apisarnthanarak A, Khoury H, Reinus W et al. Severe Clostridium difficile colitis: the role of intracolonic vancomycin. Am J Med. 2002; 112:328-9.
61. Bublin JG, Barton TL. Rectal use of vancomycin. Ann Pharmacother. 1994; 28:1357.
62. Pasic M, Jost R, Carrel T et al. Intracolonic vancomycin for pseudomembranous colitis. N Engl J Med. 1993; 329:583. Letter.
63. Silva J Jr. Update on pseudomembranous colitis. West J Med. 1989; 151:644-8.
64. Goodpasture HC, Dolan PJ Jr, Jacobs ER et al. Pseudomembranous colitis and antibiotics. Kans Med. 1986; 87:133,146.
65. Currie BP, Lemos-Filho L. Evidence for biliary excretion of vancomycin into stool during intravenous therapy: potential implications for rectal colonization with vancomycin-resistant enterococci. Antimicrob Agents Chemother. 2004; 48:4427-9.
66. McVay CS, Rolfe RD. In vitro and in vivo activities of nitazoxanide against Clostridium difficile. Antimicrob Agents Chemother. 2000; 44:2254-8.
67. Pepin J, Alary ME, Valiquette L et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis. 2005; 40:1591-7.
68. Musher DM, Aslam S, Logan N et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis. 2005; 40:1586-90.
69. Nair S, Yadav D, Corpuz M et al. Clostridium difficile colitis: factors influencing treatment failure and relapse - a prospective evaluation. Am J Gastroenterol. 1998; 93:1873-6.
70. Johnson S, Schriever C, Galang M et al. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis. 2007; 44:846-8.
71. Kyne L, Warny M, Qamar A et al. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med. 2000; 342:390-7.
72. Juang P, Skledar SJ, Zgheib NK et al. Clinical outcomes of intravenous immune globulin in severe Clostridium difficile-associated diarrhea. Am J Infect Control. 2007; 35:131-7.
73. Wilcox MH. Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhea. J Antimicrob Chemother. 2004; 53:882-4.
74. McPherson S, Rees CJ, Ellis R et al. Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea. Dis Colon Rectum. 2006; 49:640-5.
75. Salcedo J, Keates S, Pothoulakis C et al. Intravenous immunoglobulin therapy for severe Clostridium difficile colitis. Gut. 1997; 41:366-70.
76. Naaber P, Smidt I, Stsepetova J et al. Inhibition of Clostridium difficile strains by intestinal Lactobacillus species. J Med Microbiol. 2004; 53:551-4.
77. Wullt M, Hagslatt ML, Odenholt I. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile- associated diarrhea: a double-blind, placebo-controlled trial. Scand J Infect Dis. 2003; 35:365-7.
78. Pothoulakis C, Kelly CP, Joshi MA et al. Saccharomyces boulardii inhibits Clostridium difficile toxin A binding and enterotoxicity in rat ileum. Gastroenterology. 1993; 104:1108-15.
79. Can M, Besirbellioglu BA, Avci IY et al. Prophylactic Saccharomyces boulardii in the prevention of antibiotic-associated diarrhea: a prospective study. Med Sci Monit. 2006; 12:PI19-22.
80. Elmer GW, McFarland LV, Surawicz CM et al. Aliment Pharmacol Ther. 1999; 13:1663-8.
81. Lewis SJ, Potts LF, Barry RE. The lack of therapeutic effect of Saccharomyces boulardii in the prevention of antibiotic-related diarrhoea in elderly patients. J Infect. 1998; 36:171-4.
82. Cherifi S, Robberecht J, Miendje Y. Saccharomyces cerevisiae fungemia in an elderly patient with Clostridium difficile colitis. Acta Clin Belg. 2004; 59:223-4.
83. Riquelme AJ, Calvo MA, Guzman AM et al. Saccharomyces cerevisiae fungemia after Saccharomyces boulardii treatment in immunocompromised patients. J Clin Gastroenterol. 2003; 36:41-3.
84. Valente P, Gouveia FC, de Lemos GA. PCR amplification of the rDNA internal transcribed spacer region for differentiation of Saccharomyces cultures. FEMS Microbiol Lett. 1996; 137:253-6.
85. Basseti S, Frei R, Zimmerli W et al. Fungemia with Saccharomyces cerevisiae after treatment with Saccharomyces boulardii. Am J Med. 1998; 105:71-2.
86. Piarroux R, Millon L, Bardonnet K et al. Are live saccharomyces yeasts harmful to patients? Lancet. 1999; 353:1851-2.
87. Lewis S, Burmeister S, Brazier J. Effect of the prebiotic oligofructose on relapse of Clostridium difficile-associated diarrhea: a randomized, controlled study. Clin Gastroenterol Hepatol. 2005; 3:442-8.
88. Lewis S, Burmeister S, Cohen S et al. Failure of dietary oligofructose to prevent antibiotic-associated diarrhea. Aliment Pharmacol Ther. 2005; 21:469-77.
89. Lawrence SJ, Korzenik JR, Mundy LM. Probiotics for recurrent Clostridium difficile disease. J Med Microbiol. 2005; 54:905-6.
90. Dendukuri N, Costa V, McGregor M et al. Probiotic therapy for the prevention and treatment of Clostridium difficile- associated diarrhea: a systematic review. CMAJ. 2005; 173:167-70.
91. Bowden TA, Mansberger AR, Lykins LE. Pseudomembranous enterocolitis: mechanism for restoring floral homeostasis. Am Surg. 1981; 47:178-83.
92. Scwan A, Sjolin S, Trottestam U et al. Relapsing Clostridium difficile enterocolitis cured by rectal infusion of normal faeces. Scand J Infect Dis. 1984; 16:211-5.
93. Gustafsson A, Lund-Tonnesen S, Berstad A et al. Faecal short-chain fatty acids in patients with antibiotic-associated diarrhoea, before and after faecal enema treatment. Scand J Gastroenterol. 1998; 33:721-7.
94. Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis. 2003; 36:580-5.
95. Tvede M, Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhea in six patients. Lancet. 1989; 27:1156-60.
96. Fernandez A, Anand G, Friedenberg F. Factors associated with failure of metronidazole in Clostridium difficile- associated disease. J Clin Gastroenterol. 2004; 38:414-8.
97. Aspevall OL, Lundberg A, Burman LG et al. Antimicrobial susceptibility pattern of Clostridium difficile and its relation to PCR ribotypes in a Swedish university hospital. Antimicrob Agents Chemother. 2006; 50:1890-2.
98. Pelaez T, Alcala L, Alonso R et al. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother. 2002; 46:1647-50.
99. Pelaez T, Alcala L, Alonso R et al. In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or resistance to metronidazole. Antimicrob Agents Chemother. 2005; 49:1157-9.
100. Musher DM, Aslam S, Logan N et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis. 2005; 40:1586-90.
101. Shin JW, Yong D, Kim MS et al. Sudden increase of vancomycin-resistant enterococcal infections in a Korean tertiary care hospital: possible consequences of increased use of oral vancomycin. J Infect Chemother. 2003; 9:62-7,104-5.
102. Pechine S, Janoir C, Collignon A. Variability of Clostridium difficile surface proteins and specific serum antibody response in patients with Clostridium difficile-associated disease. J Clin Microbiol. 2005; 43:5018-25.
103. Kyne L, Warny M, Qamar A et al. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhea. Lancet. 2001; 357:189-93.
104. Kotloff KL, Wasserman SS, Losonsky GA et al. Safety and imunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect Immun. 2001; 69:988-95.
105. Aboudola S, Kotloff KL, Kyne L et al. Clostridium difficile vaccine and serum immunoglobulin G antibody response to toxin A. Infect Immun. 2003; 71:1608-10.
106. Sougioultzis S, Kyne L, Drudy D et al. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology. 2005; 128:764-70.